natgillin/translations-raw huggingface dataset:
During postpartum: Following a possible decrease in atazanavir exposure during the second and third trimester, atazanavir exposures might increase during the first two months after delivery (see section 5.2).
Tijekom postpartalnog razdoblja: Nakon mogućeg smanjenja izloženosti atazanaviru tijekom drugog i trećeg tromjesečja, izloženost atazanaviru može biti povećana tijekom prva dva mjeseca nakon porođaja (vidjeti dio 5.2).
When transitioning between formulations, a change in dose may be needed.
Kada se prelazi na s jedne formulacije na drugu, možda će biti potrebna promjena doze.
REYATAZ/ritonavir, especially when commencing therapy.
REYATAZ/ritonavirom, osobito na početku terapije.
Your doctor may adjust the dose of REYATAZ according to your anti-HIV therapy.
Liječnik će možda prilagoditi dozu lijeka REYATAZ prema Vašoj anti-HIV terapiji.
The safety profile in this study was overall comparable to that seen in adults.
Sigurnosni profil u ovom je ispitivanju općenito bio usporediv s onime u odraslih.
Pharmacotherapeutic group: antivirals for systemic use, protease inhibitors, ATC code: J05AE08
Farmakoterapijska skupina: antivirotici za sistemsku primjenu, inhibitori proteaze, ATK oznaka: J05AE08
REYATAZ oral powder should be taken/given with food (e.g. applesauce or yogurt) or drinks (e.g. milk, infant formula or water) for infants who can drink from a cup.
REYATAZ oralni prašak treba uzeti/dati s hranom (npr. kašica od jabuke ili jogurt) ili s pićem (npr. mlijeko, dojenačka formula ili voda) za dojenčad koja može piti iz čaše.
Children receiving REYATAZ may require their heart to be monitored.
Kod djece koja uzimaju REYATAZ možda će biti potrebno pratiti rad srca.
If REYATAZ oral powder is mixed with water, food should also be taken at the same time.
Ako se REYATAZ oralni prašak miješa s vodom, istovremeno treba također uzeti hranu.
What REYATAZ contains
Što REYATAZ sadrži
REYATAZ is not a cure for HIV infection.
REYATAZ neće izliječiti HIV-infekciju.
Your doctor has prescribed REYATAZ for you because you are infected by the HIV that causes Acquired Immunodeficiency Syndrome (AIDS).
Liječnik Vam je propisao REYATAZ zato što ste zaraženi HIV-om koji uzrokuje sindrom stečene imunodeficijencije (SIDA).
Race: a population pharmacokinetic analysis of samples from Phase II clinical trials indicated no effect of race on the pharmacokinetics of atazanavir.
Rasa: Analiza populacijske farmakokinetike uzoraka iz kliničkih ispitivanja faze II pokazala je da rasa ne utječe na farmakokinetiku atazanavira.
The study assessed 40 infants who received antiretroviral prophylactic treatment (which did not include REYATAZ) and were negative for HIV-1 DNA at the time of delivery and/or during the first 6 months postpartum.
Ispitivanjem se procijenilo 40 dojenčadi koja su primala antiretrovirusno profilaktičko liječenje (koje nije uključivalo REYATAZ) i bila negativna na HIV-1 DNK u vrijeme porođaja i/ili tijekom prvih šest mjeseci nakon rođenja.
The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.
Na tiskanoj uputi o lijeku mora se navesti naziv i adresa proizvođača odgovornog za puštanje navedene serije lijeka u promet.
Do not stop taking REYATAZ before talking to your doctor.
Nemojte prestati uzimati REYATAZ prije nego što o tome razgovarate s Vašim liječnikom
that co-administration with famotidine is not recommended but if required, atazanavir without ritonavir should be administered either 2 hours after famotidine or 12 hours before.
Ne preporučuje se istovremena primjena s famotidinom, ali ako je ona neophodna, atazanavir bez ritonavira treba primijeniti ili 2 sata nakon famotidina ili 12 sati prije njega.
INHALED BETA AGONISTS Salmeterol
INHALACIJSKI BETA AGONISTI Salmeterol
An initial dose reduction of diltiazem by 50% is recommended, with subsequent titration as needed and ECG monitoring.
Preporučuje se smanjenje početne doze diltiazema za 50%, uz kasniju titraciju po potrebi i elektrokardiografski nadzor.
Tell your doctor immediately if you develop any of the following serious side effects:
Odmah obavijestite liječnika ako se u Vas razvije jedna od slijedećih nuspojava:
What REYATAZ looks like and contents of the pack
Kako REYATAZ izgleda i sadržaj pakiranja
There are no dosing recommendations for REYATAZ in paediatric patients less than 3 months of age.
Nema preporuka za doziranje lijeka REYATAZ u pedijatrijskih bolesnika mlađih 3 mjeseca.
Do not take or give a double dose to make up for a forgotten dose.
Nemojte uzeti ili dati dvostruku dozu kako biste nadoknadili zaboravljenu dozu.
Aspartame provides a source of phenylalanine and, therefore, may not be suitable for persons with phenylketonuria.
Aspartam je izvor fenilalanina i stoga nije prikladan za osobe s fenilketonurijom.
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 50 mg
5. SADRŽAJ PO TEŽINI, VOLUMENU ILI DOZNOJ JEDINICI LIJEKA 50 mg
Treatment of overdose with REYATAZ should consist of general supportive measures, including monitoring of vital signs and electrocardiogram (ECG), and observations of the patient's clinical status.
Liječenje predoziranja lijekom REYATAZ treba se sastojati od općih potpornih mjera, uključujući praćenje vitalnih znakova i elektrokardiogram (EKG), te promatranja kliničkog stanja bolesnika.
For storage conditions after mixing of the medicinal product, see section 6.3.
Uvjete čuvanja nakon miješanja lijeka vidjeti u dijelu 6.3
ANTIEPILEPTICS
ANTIEPILEPTICI
It is recommended that the International Normalised Ratio (INR) be monitored carefully during treatment with REYATAZ, especially when commencing therapy.
Preporučuje se pažljivo pratiti međunarodni normalizirani omjer (INR) tijekom liječenja lijekom REYATAZ, osobito na početku terapije.
63 mg of aspartame per sachet.
63 mg aspartama po vrećici.
Distribution: atazanavir was approximately 86% bound to human serum proteins over a concentration range of 100 to 10,000 ng/ml.
Distribucija: Približno je 86% atazanavira bilo vezano za proteine u ljudskom serumu u rasponu koncentracija od 100 do 10 000 ng/ml.
Give to your child the recommended dose of ritonavir immediately after giving REYATAZ oral powder.
Preporučenu dozu ritonavira dajte svom djetetu odmah nakon primjene REYATAZ oralnog praška.
If you stop taking REYATAZ
Ako prestanete uzimati REYATAZ
Preparing and giving the medicine with food
Priprema i primjena lijeka s hranom
d Includes patients with baseline resistance data.
d Uključuje bolesnike s početnim podacima o rezistenciji.
REYATAZ oral powder contains aspartame as a sweetening agent.
REYATAZ oralni prašak sadrži aspartam kao sladilo.
1.3 g of sucrose per sachet.
1.3 g saharoze po vrećici.
OUTER CARTON TEXT (BOTTLE AND BLISTER PRESENTATIONS) AND BOTTLE LABEL TEXT
TEKST NA KUTIJI (PAKIRANJA S BOCOM I BLISTERIMA) I TEKST NA NALJEPNICI BOCE
Not all pack sizes may be marketed in all countries.
Na tržištu svih zemalja se ne moraju nalaziti sve veličine pakiranja.
Administration of REYATAZ and infant formula using an infant bottle is not recommended because the full dose may not be delivered.
Primjena lijeka REYATAZ i dojenačke formule putem dječje bočice se ne preporučuje jer se možda ne bi dala puna doza.
The mechanism of this decrease is unknown (see sections 4.2 and 4.4.
Mehanizam ovog smanjenja nije poznat. (Vidjeti dijelove 4.2 i 4.4.)
REYATAZ capsules may be used by adults and children 6 years of age and older.
REYATAZ kapsule mogu uzimati odrasli i djeca u dobi od 6 ili više godina.
Tenofovir disoproxil fumarate AUC Tenofovir disoproxil fumarate Cmax Tenofovir disoproxil fumarate Cmin
Tenofovirdizoproksilfumarat AUC Tenofovirdizoproksilfumarat Cmax Tenofovirdizoproksilfumarat Cmin
Blister pack :
Blister pakiranje:
HIV RNA <50 copies/ml, %f (responder/evaluable) All patients 36 (43/120) 32 (38/120) 42 (52/123) 35 (41/118)
HIV RNK <50 kopija/ml, %f (bolesnici s odgovorom/bolesnici koji su se mogli procijeniti) Svi bolesnici 36 (43/120) 32 (38/120) 42 (52/123) 35 (41/118)
If you miss a dose or if you forget to give your child a dose, take or give the missed dose as soon as possible with food and then take or give the next scheduled dose at its regular time.
Ako ste propustili dozu ili ste zaboravili svom djetetu dati dozu, uzmite ili dajte propuštenu dozu čim prije s hranom, a potom uzmite ili dajte sljedeću dozu prema rasporedu u uobičajeno vrijeme.
The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.
Nositelj odobrenja obavljat će zadane farmakovigilancijske aktivnosti i intervencije, detaljno objašnjene u dogovorenom Planu upravljanja rizikom, (RMP) koji se nalazi u Modulu 1.8.2 Odobrenja za stavljanje lijeka u promet te svim sljedećim dogovorenim ažuriranim verzijama RMP-a..
Hepatic impairment: atazanavir is metabolised and eliminated primarily by the liver.
Oštećenje funkcije jetre: Atazanavir se metabolizira i eliminira prvenstveno putem jetre.
Additional infant formula, beverage or food may be given after consumption of the entire mixture.
4. Dodatnu dojenačku formulu, piće ili hranu može se dati nakon što je uzeta cjelokupna mješavina.
As a general rule, it is recommended that HIV infected women not breast-feed their infants in order to avoid transmission of HIV.
Kao opće pravilo, preporučuje se da žene zaražene HIVom ne doje svoju dojenčad kako bi se izbjegao prijenos HIV-a.
It should always be used with a low dose of ritonavir and in combination with other anti-HIV medicines.
Potrebno ga je uvijek uzimati s niskom dozom ritonavira i u kombinaciji s drugim lijekovima za liječenje HIV-a.
The compound selectively inhibits the virus-specific processing of viral Gag-Pol proteins in HIV-1 infected cells, thus preventing formation of mature virions and infection of other cells.
Taj spoj selektivno inhibira za virus specifičnu obradu virusnih proteina Gag-Pol u stanicama zaraženima virusom HIV-1 te tako sprječava stvaranje zrelih viriona i infekciju drugih stanica.
Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections, and Pneumocystis jirovecii pneumonia.
Relevantni primjeri uključuju citomegalovirusni retinitis, generalizirane i/ili fokalne mikobakterijske infekcije i upalu pluća uzrokovanu s Pneumocystis jirovecii.
If it is almost time for your or your child's next dose, do not take or give the missed dose.
Ako je uskoro vrijeme da Vi i Vaše dijete primite -sljedeću dozu, nemojte uzeti ili dati propuštenu dozu.
- The active substance is atazanavir.
- Djelatna tvar je atazanavir.
For details on preparation and administration of the REYATAZ oral powder and Instructions for Use, see section 6.6.
Za detalje o pripremi i primjeni REYATAZ oralnog praška i Upute za primjenu vidjeti dio 6.6.
After mixing with food or beverage, mixture may be stored for up to 1 hour at temperatures not above 30°C.
Nakon miješanja s hranom ili pićem, mješavina se može čuvati do najviše 1 sata, na temperaturi od najviše 30°C.
REYATAZ may affect how well your kidneys work.
REYATAZ može utjecati na to kako dobro rade vaši bubrezi.
Take REYATAZ capsules with food (a meal or a substantial snack).
Uzimajte REYATAZ kapsule s hranom (uz obrok ili obilniji međuobrok).
If withdrawal of ritonavir is medically warranted under restrictive conditions (see section 4.4), special attention should be given to atazanavir interactions that may differ in the absence of ritonavir (see information below Table 2).
Ako je izostavljanje ritonavira medicinski neophodno, pod ograničenim uvjetima (vidjeti dio 4.4.), posebnu pozornost treba obratiti na interakcije koje mogu biti drugačije u odsustvu ritonavira (vidjeti informacije navedene ispod Tablice 2).
The entire dosage of REYATAZ oral powder (mixed in the liquid infant formula, beverage or food) is administered within one hour of preparation (the mixture can be left at room stored at temperatures not above 30°C during this period).
3. Cjelokupna doza REYATAZ oralnog praška (pomiješana s tekućom dojenačkom formulom, pićem ili hranom) primjenjuje se unutar jednog sata od pripreme (mješavina se može ostaviti na sobnoj temperaturi do najviše 30°C tijekom tog razdoblja).
In pregnant rabbits, gross lesions of the stomach and intestines were observed in dead or moribund does at maternal doses 2 and 4 times the highest dose administered in the definitive embryodevelopment study.
U skotnih ženki kunića opažene su velike lezije na želucu i crijevima u mrtvih ženki kunića ili ženki kunića na umoru pri maternalnim dozama koje su bile 2 ili 4 puta veće od najviše doze primijenjene u zaključnom ispitivanju embrionalnog razvoja.
Systemic lidocaine, Quinidine
Sistemski lidokain, Kinidin
≥100,000 copies/ml
≥100 000 kopija /ml
There are other medicines that may not mix with REYATAZ.
Postoje i drugi lijekovi koji se ne smiju miješati s lijekom REYATAZ.
REYATAZ capsules must be taken with ritonavir and have to be taken with food.
REYATAZ kapsule moraju se uzimati s ritonavirom i treba ih uzimati s hranom.
LIST OF EXCIPIENTS Excipients: contains lactose (see leaflet for further information).
3. POPIS POMOĆNIH TVARI Pomoćne tvari: sadrži laktozu (vidjeti uputu za dodatne informacije).
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Od zdravstvenih radnikase traži da prijave svaku sumnju na nuspojavu lijeka putem nacionalnog sustava prijave nuspojava navedenog uDodatku V.
REYATAZ given without ritonavir should not be used in pregnant patients given that it could result of suboptimal exposure of particular concern for the mother infection and vertical transmission.
REYATAZ se bez ritonavira ne smije primjenjivati u trudnica jer to može dovesti do suboptimalne izloženosti lijeku, što je osobito problematično s obzirom na majčinu infekciju i vertikalni prijenos.
REYATAZ once daily dose ritonavir once daily dose at least 5 to less than 15
Doza ritonavira jedanput na dan najmanje 5 do manje od 15
Other medicines and REYATAZ
Drugi lijekovi i REYATAZ
After mixing the oral powder with food or drinks, it may be stored at room temperature (not above 30oC) for up to 1 hour.
Nakon miješanja oralnog praška s hranom ili pićem, može se čuvati na sobnoj temperaturi (ne iznad 30oC) do najviše 1 sata.
Add an additional tablespoon in the container, mix and feed to your child again.
Dodajte dodatnu jušnu žlicu hrane u spremnik, promiješajte i ponovno nahranite dijete.
Immunosuppressants Cyclosporin Tacrolimus Sirolimus
Imunosupresivi Ciklosporin Takrolimus Sirolimus
For children who are able to drink from a cup, REYATAZ oral powder must be taken with food or drinks.
Za djecu koja mogu piti iz čaše, REYATAZ oralani prašak mora se uzeti s hranom ili pićem.
It may be harmful if you have phenylketonuria (PKU), a rare genetic disorder in which phenylalanine builds up because the body cannot remove it properly.
Može Vam naškoditi ako bolujete od fenilketonurije rijetkog genetskog poremećaja kod kojeg dolazi do nakupljanja fenilalanina jer ga tijelo ne može ukloniti na odgovarajući način.
Atazanavir, dosed 1 hr after ddI+d4T (fasted)
Atazanavir, primijenjen 1 sat nakon ddI+d4T (natašte)
Antiviral activity in vitro: atazanavir exhibits anti-HIV-1 (including all clades tested) and anti-HIV-2 activity in cell culture.
Antivirusno djelovanje in vitro: Atazanavir u staničnoj kulturi ima anti-HIV-1 (uključujući sve ispitane skupine) i anti-HIV-2 djelovanje.
No recommendation regarding dose reduction can be made; therefore, caution should be exercised if REYATAZ is coadministered with clarithromycin.
Ne može se dati preporuka za sniženje doze; stoga je potreban oprez kad se REYATAZ primjenjuje istovremeno s klaritromicinom.
If REYATAZ is co-administered with parenteral midazolam, it should be done in an intensive care unit (ICU) or similar setting which ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation.
Ako se REYATAZ primjenjuje istovremeno s parenteralnim midazolamom, to treba učiniti u jedinici intenzivnog liječenja (JIL) ili sličnom mjestu koje omogućuje pažljiv klinički nadzor i odgovarajuće zbrinjavanje u slučaju respiratorne depresije i/ili produžene sedacije.
CD4 Mean Change from Baseline, cells/mm3 All patients 110 (n=83) 122 (n=60) 121 (n=94) 154 (n=60)
CD4 prosječna promjena od početne vrijednosti, stanice/mm3 Svi bolesnici 110 (n=83) 122 (n=60) 121 (n=94) 154 (n=60)
Cardiac monitoring is recommended based on the presence of clinical findings (e.g., bradycardia).
Preporučuje se nadzor srčane funkcije na temelju kliničkih znakova (npr. bradikardije).
It should be ensured that the patient eats or drinks all the infant formula, beverage or food that contains the powder.
Potrebno je osigurati da bolesnik pojede ili popije u potpunosti dojenačku formulu, hranu ili piće koje sadrži prašak.
Assessment of the pharmacokinetics, safety, tolerability, and efficacy of REYATAZ is based on data from the open-label, multicenter clinical trial AI424-020 conducted in patients from 3 months to 21 years of age.
Procjena farmakokinetike, sigurnosti, podnošljivosti i djelotvornosti lijeka REYATAZ temelji se na podacima iz multicentričnog kliničkog ispitivanja otvorenog tipa AI424-020 koje je provedeno u bolesnika u dobi od 3 mjeseca do 21 godine.
If the patient has developed SJS or DRESS associated with the use of REYATAZ, REYATAZ may not be restarted.
Ako je bolesnik razvio SJS ili DRESS povezan s primjenom lijeka REYATAZ, REYATAZ se možda neće ponovno uvesti u terapiju.
- The other ingredients are aspartame (E951), sucrose and orange vanilla flavour.
- Drugi sastojci su. aspartam (E951), saharoza i aroma naranče ivanilije.
Renal impairment: in healthy subjects, the renal elimination of unchanged atazanavir was approximately 7% of the administered dose.
Oštećenje funkcije bubrega: U zdravih je ispitanika eliminacija neizmijenjenog atazanavira putem bubrega iznosila približno 7% primijenjene doze.
At Week 48 there were 134 paediatric patients aged 3 months to less than 11 years that received REYATAZ oral powder with ritonavir that were evaluated for efficacy.
U 48. tjednu bilo je 134 pedijatrijska bolesnika u dobi od 3 mjeseca do manje od 11 godina koji su primali REYATAZ oralni prašak s ritonavirom kojima je procijenjena djelotvornost.
- The other ingredients are crospovidone, lactose monohydrate, and magnesium stearate.
- Drugi sastojci su krospovidon, laktoza hidrat i magnezijev stearat.
For inclusion in both trials, treatment-naive patients had to have genotypic sensitivity to REYATAZ and two NRTIs, and treatment-experienced patients had to have documented genotypic and phenotypic sensitivity at screening to REYATAZ and at least 2 NRTIs.
Za uključenje u oba ispitivanja bolesnici koji prethodno nisu bili liječeni morali su imati genootipsku osjetljivost na REYATAZ i dva NRTI-ja i bolesnici koji su prethodno bili liječeni, morali su prilikom probira imati dokumentiranu genotipsku i fenotipsku osjetljivost na REYATAZ i barem 2 NRTI-ja.
Add another 15 ml of the drink, mix and have the child drink the mixture.
Dodajte dodatnih 15 ml pića, promiješajte i dajte djetetu da popije.
None of the de novo substitutions (see Table 4) are specific to atazanavir and may reflect reemergence of archived resistance on atazanavir + ritonavir in Study 045 treatment-experienced population.
Niti jedna od de novo supstitucija (vidjeti tablicu 4) nije specifična za atazanavir i može odražavati ponovnu pojavu stare rezistencije na atazanavir s ritonavirom u prethodno liječene populacije u Ispitivanju 045.
Linearity/non-linearity: the pharmacokinetics of atazanavir were evaluated in healthy adult volunteers and in HIV infected patients; significant differences were observed between the two groups.
Linearnost/ne-linearnost: Farmakokinetika atazanavira procijenjena je u zdravih odraslih dobrovoljaca i bolesnika zaraženih HIV-om; između te dvije skupine opažene su značajne razlike.
Based on data obtained with other boosted PIs and ketoconazole, where ketoconazole AUC showed a 3-fold increase, REYATAZ/ritonavir is expected to increase ketoconazole or itraconazole concentrations.
Na temelju podataka dobivenih s drugim pojačanim inhibitorima proteaze i ketokonazola, gdje je AUC ketokonazola pokazivao trostruko povećanje, očekuje se da će REYATAZ s ritonavirom povećati koncentraciju ketokonazola ili itrakonazola.
See the "Instructions for use" at the end of the package leaflet for how to prepare and give a dose of REYATAZ oral powder.
Pogledajte "Upute za uporabu" o lijeku na kraju ove upute za pripremu i primjenu doze REYATAZ oralnog praška.
Excipient with known effect: 63 mg of aspartame; 1305.15 mg of sucrose per sachet (1.5 g oral powder).
Pomoćna tvar s poznatim učinkom: 63 mg aspartama, 1305,15 mg saharoze po vrećici (1,5 g oralnog praška).
Table 5: Efficacy Outcomes in Study 138 a Parameter
Tablica 5: Ishodi djelotvornosti u Ispitivanju 138 a Parametar
If you have any questions on how to prepare or give a dose of REYATAZ oral powder, talk to your doctor, pharmacist or nurse.
U slučaju dodatnih pitanja o pripremi i primjeni doze REYATAZ oralnog praška obratite se liječniku, ljekarniku ili medicinskoj sestri.
Skin rash, itching that may occasionally be severe has been reported.
Osip na koži, prijavljen je svrbež koji ponekad može biti težak.
Preparing and giving the medicine with liquid infant formula using a medicine cup or small container and oral syringe (ask your pharmacist for an oral syringe):
Priprema i primjena lijeka s tekućom dojenačkom formulom korištenjem medicinske čaše ili malog spremnika i oralne štrcaljke (zatražite od svog ljekarnika oralnu štrcaljku):
During attempts to overcome the decreased exposure by increasing the dose of REYATAZ or other protease inhibitors with ritonavir, a high frequency of liver reactions was seen.
Tijekom pokušaja da se prevlada smanjena izloženost povećanjem doze lijeka REYATAZ ili drugih inhibitora proteaze s ritonavirom, opažena je velika učestalost jetrenih reakcija.
REYATAZ 300 mg with ritonavir 100 mg may not provide sufficient exposure to atazanavir, especially when the activity of atazanavir or the whole regimen may be compromised due to drug resistance.
REYATAZ od 300 mg s ritonavirom od 100 mg možda neće osigurati dovoljnu izloženost atazanaviru, osobito kad djelovanje atazanavira ili cijelog terapijskog protokola može biti promijenjeno zbog rezistencije na lijek.
Yellowing of your skin or the white part of your eyes caused by high levels of bilirubin in your blood has been commonly reported.
Često je prijavljeno žutilo kože ili bjeloočnica koje je uzrokovano povišenim razinama bilirubina u Vašoj krvi.
REYATAZ should not be used in children less than 3 months because of safety concerns especially taking into account the potential risk of kernicterus.
REYATAZ se ne smije primijenjivati u djece mlađe od 3 mjeseca zbog sigurnosnih razloga, osobito kada se uzme u obzir mogući rizik od kernikterusa.
Do not use this medicine after the expiry date which is stated on the label, carton or blister.
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na naljepnici, kutiji ili blisteru.
Table 5: Efficacy Outcomes in Study 138 a
Tablica 5: Ishodi djelotvornosti u Ispitivanju 138 a
Symptoms of gallbladder problems may include pain in the right or middle upper stomach area, nausea, vomiting, fever or yellowing your skin or the white part of your eyes.
Simptomi problema sa žučnim kamencima mogu uključivati bol u desnom ili srednjem gornjem dijelu trbuha, mučninu, povraćanje, vrućicu ili žutilo kože ili bjeloočnica.
Assessment of the pharmacokinetics, safety, tolerability, and virologic response of REYATAZ oral powder was based on data from two open-label, multicenter clinical trials.
Procjena farmakokinetike, sigurnosti, podnošljivosti i virološkog odgovora REYATAZ oralnog praška temeljena je na podacima dva otvorena multicentirična klinička ispitivanja:
Pregnancy and Postpartum
Trudnoća i postpartalno razdoblje
One pack size is available: 1 carton with 30 sachets.
Dostupno je pakiranje: 1 kutija s 30 vrećica